This page contains enriched content visible when JavaScript is enabled or by clicking here. Skip to Main Content

Research Ethics/Article Retraction

Biogen re-evaluated the data a number of times and eventually suggested there was an improvement in mental capacity among dementia sufferers – of less than one per cent....Worryingly, safety data published in November showed that 41 per cent of patients who took the drug suffered major side effects. The most serious of these include a type of swelling and bleeding in the brain known as ARIA-E. An FDA Adverse Event Reporting System case report shows that at least one woman died from this complication." -- Daily Mail


"...[B]ombshell allegations that a pivotal study on the cause of Alzheimer’s disease contained manipulated results, potentially leading other scientists down a blind alley, hindering the development of effective treatments and giving false hope to patients and their families." -- Daily Mail

"Pharmaceutical companies over more than a decade have spent billions of dollars on research to find a treatment for Alzheimer's. Research has largely focused on the beta amyloid protein, which accumulates in the brains of patients with Alzheimer's years before they experience memory loss. Researchers have hypothesized that the buildup in the brain from the beta-amyloid was responsible for the cognitive decline seen in Alzheimer's patients.  However, an estimated 150 to 300 experimental Alzheimer's treatments have failed to show clinical benefits—and many of those treatments targeted the beta amyloid protein." --

"But the Science investigation, following so many failed amyloid beta drug trials, suggests a colossal scientific failure that may have led to needless suffering by those living with Alzheimer’s Disease and their family members." --

The company is now facing an investigation from the Securities and Exchange Commission (SEC), and has had some of its trial data either rescinded or marked by journals as potentially manipulated." -- Daily Mail

Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug "Cassava has received more than $20 million from the U.S. National Institutes of Health to support developing simufilam...Research misconduct may distort NIH funding decisions, the overall integrity of the research we support and the public's trust in science and resulting outcomes." --